An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical ...

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

This may not apply in your husband’s case, but it’s worth having the conversation. The two meds Goldstein prescribes for men are flibanserin (Addyi), an oral tablet taken d ...

The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have been unclear, pending long-term follow-up data from randomized controlled ...

Watchdog finds failings in prostate cancer treatment in North Wales going back almost a decade.

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

I’m sure I enjoyed them as a child, though my brain has not retained a single memory of any birthday from my youth. I do, ...